Published in Haematologica on November 01, 2015
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med (1987) 3.82
Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol (2010) 3.67
A second serine protease associated with mannan-binding lectin that activates complement. Nature (1997) 3.64
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Autoimmune hemolytic anemia. Am J Hematol (2002) 3.01
Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med (1992) 2.76
Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today (1996) 2.74
How I treat autoimmune hemolytic anemias in adults. Blood (2010) 2.38
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
How I treat paroxysmal nocturnal hemoglobinuria. Blood (2009) 1.97
C1q, autoimmunity and apoptosis. Immunobiology (2002) 1.94
High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood (2010) 1.91
TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood (2014) 1.90
Cold antibody autoimmune hemolytic anemias. Blood Rev (2007) 1.89
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood (2011) 1.82
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
Heme oxygenase-1: from biology to therapeutic potential. Trends Mol Med (2009) 1.63
Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol (2006) 1.63
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood (2009) 1.59
Eculizumab. Nat Rev Drug Discov (2007) 1.56
Hemolytic anemia due to warm autoantibodies. Blood Rev (2007) 1.55
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood (2014) 1.55
Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest (1974) 1.54
C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev (2000) 1.52
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Complement is activated by IgG hexamers assembled at the cell surface. Science (2014) 1.52
How I manage cold agglutinin disease. Br J Haematol (2011) 1.48
Therapeutic inhibition of the complement system. Pharmacol Rev (1998) 1.38
Cold hemolytic syndrome. Hematology Am Soc Hematol Educ Program (2006) 1.35
Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med (1989) 1.34
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Ultrastructure of the membrane attack complex of complement: detection of the tetramolecular C9-polymerizing complex C5b-8. Proc Natl Acad Sci U S A (1982) 1.30
C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J (1979) 1.28
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood (2014) 1.22
Solution structure of human and mouse immunoglobulin M by synchrotron X-ray scattering and molecular graphics modelling. A possible mechanism for complement activation. J Mol Biol (1991) 1.18
Autoimmune haemolytic anaemia - a practical guide to cope with a diagnostic and therapeutic challenge. Neth J Med (2011) 1.18
Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood (2013) 1.17
Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica (2010) 1.13
Long-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease. Blood (2009) 1.08
Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol (2013) 1.07
Inhibition of heparin/protamine complex-induced complement activation by Compstatin in baboons. Clin Immunol (2000) 1.06
Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood (2003) 1.03
Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol (2010) 1.00
Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol (1998) 0.99
C1-inhibitor: more than a serine protease inhibitor. Semin Thromb Hemost (2011) 0.99
Complement, cold agglutinins, and therapy. Blood (2014) 0.98
J chain synthesis and secretion of hexameric IgM is differentially regulated by lipopolysaccharide and interleukin 5. Proc Natl Acad Sci U S A (1992) 0.94
C1-esterase inhibitor concentrate rescues erythrocytes from complement-mediated destruction in autoimmune hemolytic anemia. Blood (2013) 0.94
Long-term response of refractory primary cold agglutinin disease to eculizumab therapy. Ann Hematol (2013) 0.93
Hematin promotes complement alternative pathway-mediated deposition of C3 activation fragments on human erythrocytes: potential implications for the pathogenesis of anemia in malaria. J Immunol (2007) 0.93
An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol (2013) 0.90
An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA. Am J Transplant (2015) 0.89
Immunoglobulin flexibility in complement activation. Immunol Today (1986) 0.89
TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs (2001) 0.88
Correlations between quantitative assay of red cell-bound C3, serologic reactions, and hemolytic anemia. Blood (1974) 0.86
Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med (2000) 0.86
C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther (2008) 0.85
Disseminated intravascular coagulation due to IgM-mediated autoimmune hemolytic anemia. Pediatr Blood Cancer (2011) 0.82
Heme interacts with c1q and inhibits the classical complement pathway. J Biol Chem (2011) 0.82
Iron ions and haeme modulate the binding properties of complement subcomponent C1q and of immunoglobulins. Scand J Immunol (2007) 0.81
Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab. Eur J Haematol (2011) 0.79
Acute massive intravascular hemolysis and disseminated intravascular coagulation. Southeast Asian J Trop Med Public Health (1979) 0.76
A man with "black fingers". Cold agglutinin disease (CAD). Neth J Med (2014) 0.76
Thanks for the complement (inhibitor). Blood (2011) 0.76